CommercialCoverageMedium impact
08.01.80e, Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®)
Independence Blue Cross·Psychiatry, Pain Management, Anesthesiology·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Policy 08.01.80e covering intravenous ketamine (Ketalar®) and intranasal esketamine (Spravato®) was updated and then immediately removed. The policy was effective 01/01/2026, revised 02/10/2026, and removed 02/11/2026, indicating this may have been a temporary or erroneous policy update.
Action Required
Immediately: Billing team should verify current coverage guidelines for ketamine and esketamine services by contacting the payer directly or checking for replacement policy guidance, as this policy was removed the day after posting. Do not rely on this removed policy for billing decisions.